Skip to Main Content
Contribute Try STAT+ Today

A host of burgeoning fields in biomedicine — from personalized therapies and CRISPR gene editing to targeted tumor diagnostics — depend on the ability of labs to synthesize DNA on demand, cheaply and reliably.

Innovators in the field like San Francisco-based Twist Bioscience and Cambridge, Mass.-based Gen 9 use silicon wafers and microarrays to scale up the process, but are still using the same basic chemical techniques pioneered some 30 years ago. Now, a tiny ten-person startup in San Diego called Molecular Assemblies Inc. is nudging into the field with an entirely new process that uses enzymes instead of chemicals to create DNA. The technique was co-invented by one of the company’s founders, William Efcavitch, who also helped pioneered the chemical technique for synthesizing DNA that is in widespread use today.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.